Pharmaceutical - Asia-Pacific, Tropical diseases

Filter

Popular Filters

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

11-11-2013

Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

Eisai gains WHO prequalification for DEC; launches high-dose Aricept in Korea

27-08-2013

Japanese drug major Eisai (TYO: 4523) has received prequalification from the World Health Organization…

AriceptAsia-PacificdiethylcarbamazineEisaiMarkets & MarketingNeurologicalPharmaceuticalRegulationTropical diseases

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Astellas collaborates with AIST for neglected tropical diseases

23-10-2012

Japanese drug major Astellas Pharma (TYO: 4503) has signed a collaborative drug discovery research agreement…

Asia-PacificAstellas PharmaPharmaceuticalResearchTropical diseases

Ranbaxy debuts first Indian-developed malaria drug, Synriam

27-04-2012

Indian drug major Ranbaxy (AB: B) said yesterday - coinciding with World Malaria Day - that it is "opening…

Asia-PacificDaiichi SankyoMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSynriamTropical diseases

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top